Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Sarita Sharma

Geriatric Medicine Hagerstown, MD Medical Doctor

NPI 1902808835 CMS profile 531221

12916 Conamar Dr, Suite 204, Hagerstown, MD 21742

Open in the dashboard

General payments

$327

19 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Sarita Sharma of Hagerstown, MD is reported in the CMS Open Payments database as having received $327 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $14 1
2022 General $15 1
2021 General $146 8
2020 General $115 6
2019 General $37 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarita Sharma
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Sarita Sharma were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Sarita Sharma Geriatric Medicine median Middle half National median
2019 $37 $96 $28–$339 $163
2020 $115 $99 $28–$262 $114
2021 $146 $94 $27–$318 $132
2022 $15 $103 $34–$338 $149
2023 $14 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $214 11 payments
  2. Novo Nordisk Inc $113 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $327 19 payments
Products named General payments · program years 2019–2023
  1. JARDIANCE $167 9 payments
  2. Ozempic $113 8 payments
  3. RYBELSUS $76 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,460

Median for Family Practice: 1,826

Drug cost

$341,875

Median for Family Practice: $120,094

Branded share of claims

14.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 25 $55,325
Eliquis Apixaban Brand 37 $43,708
Mounjaro Tirzepatide Brand 26 $42,747
Januvia Sitagliptin Phosphate Brand 19 $29,634
Ozempic Semaglutide Brand 22 $29,559
Jardiance Empagliflozin Brand 11 $18,187
Spiriva Handihaler Tiotropium Bromide Brand 20 $13,245
Xarelto Rivaroxaban Brand 14 $12,891
Myrbetriq Mirabegron Brand 18 $10,857
Atorvastatin Calcium Generic 357 $5,952

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$101,466

Of which drugs: $12,866

Medicare patients

361

Average age 74

Services billed

1,769

238 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Depression 33%
Diabetes 28%
Ischemic heart disease 25%
Chronic kidney disease 25%
COPD 21%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 35 36 $5,226
Vaccine for influenza for injection into muscle 90662 Office 62 62 $4,991
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 19 53 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record